AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3067924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen t.i.d. (thrice daily)
Number of subjects: 40
Study 30227841 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally enhanced pain coping skills training (CST) program
Number of subjects: 0
Study 26278222 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support service (depression self-management training, recovery coaching, care coordination)
Number of subjects: 302
Study 26278222 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 302
Study 24350662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin patch
Number of subjects: 1530
Study 24350662 — intervention group
Group type: COMPARATOR
Intervention: Propiverine
Number of subjects: 1530
Study 24350662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1530
Study 22500659 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program (specific asanas, pranayamas, meditation, yogic counselling, lectures on yoga philosophy)
Number of subjects: 80
Study 22500659 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 80
Study 22500659 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy exercises (control group)
Number of subjects: 80
Study 19500939 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CPR
Number of subjects: 106
Study 19500939 — intervention group
Group type: COMPARATOR
Intervention: Over-the-head CPR
Number of subjects: 106
Study 18269639 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M group)
Number of subjects: 30
Study 18269639 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (G group)
Number of subjects: 30
Study 18269639 — intervention group
Group type: COMPARATOR
Intervention: Control (C group)
Number of subjects: 30
Study 16003735 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 131178
Study 16003735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 131178
Study 16003735 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV
Number of subjects: 131178
Study 12942563 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg as a 15-minute infusion)
Number of subjects: 74
Study 10632128 — intervention group
Group type: EXPERIMENTAL
Intervention: G-suit inflation with LBNP (50 mm Hg)
Number of subjects: 12
Study 10632128 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline without G-suit and LBNP)
Number of subjects: 12
Study 10632128 — intervention group
Group type: COMPARATOR
Intervention: LBNP (50 mm Hg)
Number of subjects: 12
Study 8867251 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Ro 15‐8081 (divided into 2 doses)
Number of subjects: 522
Study 8867251 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg/day, piroxicam in the morning and placebo in the evening)
Number of subjects: 522
Study 8867251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 522
Study 1325728 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine
Number of subjects: 40
Study 1325728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6334234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 52
Study 6334234 — intervention group
Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 52
Study 31119758 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated fight response against an angry opponent
Number of subjects: 0
Study 31119758 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated fight with aversive white noise after losing
Number of subjects: 0
Study 31119758 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive noise after losing to an angry opponent
Number of subjects: 0
Study 31119758 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of aversive noise after losing to an angry opponent
Number of subjects: 0
Study 28832393 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg body mass)
Number of subjects: 9
Study 28832393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 27605955 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic phenylephrine weight adjusted dose infusion at 0.5 micrograms per kilogram per minute
Number of subjects: 108
Study 27605955 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic phenylephrine fixed dose infusion at 37.5 micrograms per minute
Number of subjects: 108
Study 27605955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 25240737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tips booklet intervention
Number of subjects: 120
Study 25240737 — intervention group
Group type: COMPARATOR
Intervention: Control fact sheet
Number of subjects: 120
Study 22157370 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 481
Study 22157370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 19544555 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 40
Study 19544555 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal participants, age and sex matched)
Number of subjects: 40
Study 17414226 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 200 mg twice daily
Number of subjects: 117
Study 17414226 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 117
Study 17414226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 15746789 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 60
Study 15746789 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 60
Study 15746789 — intervention group
Group type: COMPARATOR
Intervention: Harmonic Scalpel (HS) and Electrocautery
Number of subjects: 60
Study 12538373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine-bicarbonate
Number of subjects: 27
Study 12538373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-epinephrine
Number of subjects: 27
Study 12538373 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 27
Study 10759934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericranial injection of 10 x 20 mouse units botulinum toxin A
Number of subjects: 21
Study 10759934 — intervention group
Group type: COMPARATOR
Intervention: Injection of isotonic saline (placebo)
Number of subjects: 21
Study 8785134 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20
Study 8785134 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study 1993808 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (reduced dose)
Number of subjects: 28
Study 1993808 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (maintained dose)
Number of subjects: 28
Study 6467838 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting plasma noradrenaline levels in females
Number of subjects: 90
Study 6467838 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting plasma adrenaline levels in males
Number of subjects: 90
Study 6467838 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma noradrenaline concentration after isometric exercise, mental arithmetic and cold pressor testing
Number of subjects: 90
Study 6467838 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting noradrenaline concentration in males
Number of subjects: 90
Study 6467838 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting noradrenaline concentration in females
Number of subjects: 90
Study 29359339 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal implants (adapted to soft tissue thickness)
Number of subjects: 25
Study 29359339 — intervention group
Group type: COMPARATOR
Intervention: Equicrestal implants (control)
Number of subjects: 25
Study 28893309 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone/naloxone (OXN-CR)
Number of subjects: 128
Study 28893309 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release oxycodone (OX-CR)
Number of subjects: 128
Study 25339501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal biacuplasty (IDB) treatment
Number of subjects: 57
Study 25339501 — intervention group
Group type: COMPARATOR
Intervention: Cross-over from sham to IDB treatment
Number of subjects: 57
Study 24184428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 171
Study 24184428 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 171
Study 24184428 — intervention group
Group type: COMPARATOR
Intervention: Minimal Attention (MA)
Number of subjects: 171
Study 21388602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBT-D)
Number of subjects: 165
Study 21388602 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training control (RTC)
Number of subjects: 165
Study 18208600 — intervention group
Group type: EXPERIMENTAL
Intervention: Active test product (Hyal-Joint) 80 mg/day
Number of subjects: 20
Study 18208600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16364496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein preload
Number of subjects: 42
Study 16364496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofu preload
Number of subjects: 42
Study 16364496 — intervention group
Group type: COMPARATOR
Intervention: Chicken preload
Number of subjects: 42
Study 16364496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein and Tofu preloads
Number of subjects: 42
Study 12760974 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 15
Study 12760974 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 15
Study 12760974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 15
Study 10883868 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 29
Study 10883868 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 29
Study 9228104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-field MR system (1.5 T)
Number of subjects: 20
Study 9228104 — intervention group
Group type: COMPARATOR
Intervention: Low-field MR system (0.2 T)
Number of subjects: 20
Study 1580284 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg once daily
Number of subjects: 190
Study 1580284 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25 mg once daily
Number of subjects: 190
Study 1580284 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 190
Study 1580284 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 190
Study 6367326 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 157
Study 6367326 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 157
Study 30920122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 800 mg/day
Number of subjects: 0
Study 30920122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 600 mg/day
Number of subjects: 0
Study 30920122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg/day
Number of subjects: 0
Study 30920122 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated dose-reduction strategy of Sorafenib 800 mg/day for initial two cycles followed by dose reductions
Number of subjects: 0
Study 29340321 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (modified CTLA4‐Ig) administered for 4 months
Number of subjects: 90
Study 29340321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study 27696017 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation at 780 nm, 40 mW, 4 J/cm2 (G3)
Number of subjects: 60
Study 27696017 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser irradiation at 780 nm, 40 mW, 40 J/cm2 (G4)
Number of subjects: 60
Study 27696017 — intervention group
Group type: COMPARATOR
Intervention: Laser placebo-sham irradiation (G2)
Number of subjects: 60
Study 27696017 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 60
Study 24127838 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation (PVS) device (FERTI CARE(®) vibrator), used daily for at least 1 week before surgery and for 6 weeks after catheter removal.
Number of subjects: 68
Study 24127838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PVS intervention).
Number of subjects: 68
Study 22103808 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) during isoflurane anesthesia (n = 20)
Number of subjects: 72
Study 22103808 — intervention group
Group type: COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC) during propofol anesthesia (n = 14)
Number of subjects: 72
Study 20202536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g oral acetaminophen
Number of subjects: 160
Study 20202536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17993955 — intervention group
Group type: EXPERIMENTAL
Intervention: Successfully nonoperatively managed splenic injuries (n=15)
Number of subjects: 40
Study 17993955 — intervention group
Group type: COMPARATOR
Intervention: Splenectomies (n=14)
Number of subjects: 40
Study 17993955 — intervention group
Group type: COMPARATOR
Intervention: Controls with normal splenic function (n=15)
Number of subjects: 40
Study 15794175 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on melatonin
Number of subjects: 31
Study 15794175 — intervention group
Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 31
Study 12473256 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 104
Study 12473256 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 104
Study 12473256 — intervention group
Group type: COMPARATOR
Intervention: Control group (run-in)
Number of subjects: 104
Study 12473256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 104
Study 9796070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high dosage streptokinase (1.5 million U/h for 6h daily, n = 77)
Number of subjects: 156
Study 9796070 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage streptokinase (100,000 U/h, n = 79)
Number of subjects: 156
Study 9796070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high dosage streptokinase (group A)
Number of subjects: 156
Study 9796070 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosage streptokinase (group B)
Number of subjects: 156
Study 8582783 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate 200 mg orally for 30 days
Number of subjects: 29
Study 8582783 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate supplementation
Number of subjects: 29
Study 8582783 — intervention group
Group type: COMPARATOR
Intervention: AZT only (control)
Number of subjects: 29
Study 2653391 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg daily
Number of subjects: 20
Study 2653391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium 1 mg/kg
Number of subjects: 0
Study 17427 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 0
Study 17427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium 0.5 mg/kg
Number of subjects: 0
Study 17427 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.08 mg/kg
Number of subjects: 0
Study 30701343 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Self Efficacy Scale (OSE)
Number of subjects: 7749
Study 29070055 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic internal drainage (Group A)
Number of subjects: 76
Study 29070055 — intervention group
Group type: COMPARATOR
Intervention: Open excision after arthroscopic treatment (Group B)
Number of subjects: 76
Study 29070055 — intervention group
Group type: COMPARATOR
Intervention: Open excision (Group C)
Number of subjects: 76
Study 25349226 — intervention group
Group type: EXPERIMENTAL
Intervention: ECVUE™
Number of subjects: 42
Study 25349226 — intervention group
Group type: COMPARATOR
Intervention: 12-lead ECG algorithms
Number of subjects: 42
Study 23044387 — intervention group
Group type: EXPERIMENTAL
Intervention: FluroShield (F) sealant
Number of subjects: 72
Study 23044387 — intervention group
Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma (H) sealant
Number of subjects: 72
Study 23044387 — intervention group
Group type: COMPARATOR
Intervention: All groups (including both sealants)
Number of subjects: 72
Study 21729974 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 69
Study 21729974 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting
Number of subjects: 69
Study 21729974 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 69
Study 19632965 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT) for 6 hours a day during waking hours for 4 weeks
Number of subjects: 27
Study 19632965 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy only (Control)
Number of subjects: 27
Study 17489733 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 as a marker for resistance to cisplatin
Number of subjects: 0
Study 17489733 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular markers (e.g., ERCC1)
Number of subjects: 0
Study 16253073 — intervention group
Group type: EXPERIMENTAL
Intervention: TUMT followed by BD
Number of subjects: 40
Study 16253073 — intervention group
Group type: COMPARATOR
Intervention: TUMT alone
Number of subjects: 40
Study 12201933 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-1 adrenoceptor antagonists (alpha-1ARA)
Number of subjects: 39
Study 12201933 — intervention group
Group type: COMPARATOR
Intervention: preoperative untreated group
Number of subjects: 39
Study 9659537 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 112
Study 9659537 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (oral dose titrated twice daily)
Number of subjects: 112
Study 8133107 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural rotavirus infection
Number of subjects: 235
Study 8133107 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic rotavirus infection
Number of subjects: 235
Study 2777567 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received touch and verbal interaction during weaning)
Number of subjects: 26
Study 2777567 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive touch and verbal interaction)
Number of subjects: 26
Study 4808433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellsworth House community rehabilitation program
Number of subjects: 0
Study 4808433 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (remained in the jail system)
Number of subjects: 0
Study 31866387 — intervention group
Group type: EXPERIMENTAL
Intervention: Chain community pharmacies (CVS, Walgreens, etc.)
Number of subjects: 434
Study 31866387 — intervention group
Group type: COMPARATOR
Intervention: Independent pharmacies
Number of subjects: 434
Study 31866387 — intervention group
Group type: EXPERIMENTAL
Intervention: Areas with high opioid mortality rates
Number of subjects: 434
Study 31866387 — intervention group
Group type: COMPARATOR
Intervention: Areas with low opioid mortality rates
Number of subjects: 434
Study 31866387 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall community pharmacies
Number of subjects: 434
Study 30403817 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60% VO2peak) for 45 minutes
Number of subjects: 24
Study 30403817 — intervention group
Group type: COMPARATOR
Intervention: Seated rest for 45 minutes
Number of subjects: 24
Study 30403817 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) post-exercise (24 hours)
Number of subjects: 24
Study 27598045 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary abdominal aortic occlusion
Number of subjects: 105
Study 27598045 — intervention group
Group type: COMPARATOR
Intervention: Bilateral internal iliac artery occlusion
Number of subjects: 105
Study 25159300 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of teneligliptin every day (Group A)
Number of subjects: 51
Study 25159300 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of teneligliptin every other day (Group B)
Number of subjects: 51
Study 23017585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) - 1 capsule daily containing 1·2 × 10(9) colony-forming units for 12 weeks
Number of subjects: 60
Study 23017585 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) - 1 capsule daily for 12 weeks
Number of subjects: 60
Study 23017585 — intervention group
Group type: COMPARATOR
Intervention: Placebo - same product without bacteria for 12 weeks
Number of subjects: 60
Study 21771722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2505
Study 21771722 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 2505
Study 19500037 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of IgG to VSA-PAM
Number of subjects: 141
Study 19500037 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of opsonizing antibodies to CS2 IEs
Number of subjects: 141
Study 16371604 — intervention group
Group type: EXPERIMENTAL
Intervention: iv iron alone (200 mg of iron sucrose on POD 1, 2, and 3)
Number of subjects: 38
Study 16371604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iv iron and EPO (600 U x kg(‐1) on POD 1 and 3)
Number of subjects: 38
Study 16371604 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 38
Study 12527999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 76
Study 12527999 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 76